Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors

被引：4
|
作者：
Schadendorf, D. [1 ]
Wolchok, J. [2 ]
Neyns, B. [3 ]
Lebbe, C. [4 ]
Harmankaya, K. [5 ]
Verschraegen, C. [6 ]
Chin, K. [7 ]
de Pril, V. [8 ]
Hoos, A. [7 ]
Maio, M. [9 ]
机构：
[1] Univ Hosp Essen, Dept Dermatol, Essen, Germany
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[3] Univ Ziekenhuis St Rafael, Dept Oncol, Brussels, Belgium
[4] Hop St Louis, Dept Dermatol, Paris, France
[5] Med Univ Vienna, Dept Dermatol, Vienna, Austria
[6] Univ New Mexico, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA
[7] Bristol Myers Squibb Co, Global Clin Res Oncol, Wallingford, CT 06492 USA
[8] Bristol Myers Squibb Co, Global Biometr & Sci, Braine Lalleud, Belgium
[9] Univ Hosp Siena, Dept Oncol, Siena, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71952-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：579 / 579
页数：1
相关论文
共 50 条
  • [31] Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results
    Hamid, Omid
    Hwu, Wen-Jen
    Richards, Jon M.
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Sznol, Mario
    Minor, David R.
    Pavlick, Anna C.
    Urba, Walter John
    Hodi, F. Stephen
    Yang, Arvin
    Michener, Tracy
    Balogh, Agnes
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] PROGNOSTIC FACTORS IN PATIENTS WITH ADVANCED MALIGNANT-MELANOMA
    PELLONI, L
    WAGENKNECHT, L
    CAVALLI, F
    ONKOLOGIE, 1981, 4 (04): : 213 - 218
  • [33] Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
    Martens, Alexander
    Wistuba-Hamprecht, Kilian
    Foppen, Marnix Geukes
    Yuan, Jianda
    Postow, Michael A.
    Wong, Phillip
    Romano, Emanuela
    Khammari, Amir
    Dreno, Brigitte
    Capone, Mariaelena
    Ascierto, Paolo A.
    Di Giacomo, Anna Maria
    Maio, Michele
    Schilling, Bastian
    Sucker, Antje
    Schadendorf, Dirk
    Hassel, Jessica C.
    Eigentler, Thomas K.
    Martus, Peter
    Wolchok, Jedd D.
    Blank, Christian
    Pawelec, Graham
    Garbe, Claus
    Weide, Benjamin
    CLINICAL CANCER RESEARCH, 2016, 22 (12) : 2908 - 2918
  • [34] Correlation between baseline parameters and overall survival in patients with advanced melanoma treated with ipilimumab.
    Foppen, Marnix Heimen Geukes
    Jordanova, Ekatarina S.
    Van Thienen, Johannes V.
    Punt, Simone
    Van de Wiel, Bart
    Haanen, John B. A. G.
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab
    Iravani, Amir
    Wallace, Roslyn
    Lo, Serigne N.
    Galligan, Anna
    Weppler, Alison M.
    Hicks, Rodney J.
    Sandhu, Shahneen
    RADIOLOGY, 2023, 307 (03)
  • [36] Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
    Anna Maria Di Giacomo
    Luana Calabrò
    Riccardo Danielli
    Ester Fonsatti
    Erica Bertocci
    Isabella Pesce
    Carolina Fazio
    Ornella Cutaia
    Diana Giannarelli
    Clelia Miracco
    Maurizio Biagioli
    Maresa Altomonte
    Michele Maio
    Cancer Immunology, Immunotherapy, 2013, 62 : 1021 - 1028
  • [37] Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
    Di Giacomo, Anna Maria
    Calabro, Luana
    Danielli, Riccardo
    Fonsatti, Ester
    Bertocci, Erica
    Pesce, Isabella
    Fazio, Carolina
    Cutaia, Ornella
    Giannarelli, Diana
    Miracco, Clelia
    Biagioli, Maurizio
    Altomonte, Maresa
    Maio, Michele
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (06) : 1021 - 1028
  • [38] Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab
    Postow, Michael A.
    Chasalow, Scott D.
    Kuk, Deborah
    Panageas, Katherine S.
    Cheng, Michael L.
    Yuan, Jianda
    Wolchok, Jedd D.
    MELANOMA RESEARCH, 2020, 30 (01) : 71 - 75
  • [39] Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
    Ferrucci, P. F.
    Ascierto, P. A.
    Pigozzo, J.
    Del Vecchio, M.
    Maio, M.
    Cappellini, G. C. Antonini
    Guidoboni, M.
    Queirolo, P.
    Savoia, P.
    Mandala, M.
    Simeone, E.
    Valpione, S.
    Altomonte, M.
    Spagnolo, F.
    Cocorocchio, E.
    Gandini, S.
    Giannarelli, D.
    Martinoli, C.
    ANNALS OF ONCOLOGY, 2016, 27 (04) : 732 - 738
  • [40] Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006
    Long, G. V.
    Robert, C.
    Arance, A.
    Blank, C.
    Ribas, A.
    Lorigan, P.
    Mortier, L.
    Schachter, J.
    Middleton, M. R.
    Neyns, B.
    Sznol, M.
    Zhou, H.
    Ebbinghaus, S.
    Ibrahim, N.
    Steven, N.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S128 - S129
12345